Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy

Area of Science:

• Oncology
• Cancer Metabolism
• Biochemistry

Background:

• Cellular metabolism reprogramming is a key hallmark of cancer, providing energy and materials for tumor growth.
• Targeting cancer metabolism is a promising therapeutic strategy, with many inhibitors in preclinical development.
• Sarcoma research has lagged behind carcinoma in exploiting metabolic vulnerabilities.

Purpose of the Study:

• To review metabolic enzymes investigated for cancer therapies.
• To describe the therapeutic potential of targeting isocitrate dehydrogenase (IDH) mutations and succinate dehydrogenase (SDH) deficiency in sarcomas.

Main Methods:

• Review of current literature on cancer metabolism and therapeutic targets.
• Analysis of metabolic pathways including glycolysis, TCA cycle, oxidative phosphorylation (OXPHOS), glutaminolysis, pentose phosphate pathway (PPP), lipid synthesis, and amino acid/nucleotide metabolism.
• Focus on IDH and SDH as specific targets in sarcoma.

Main Results:

• Numerous metabolic pathways are under investigation for cancer therapy.
• IDH mutations and SDH deficiency are identified in specific sarcoma types, presenting novel therapeutic targets.
• Targeting these specific metabolic alterations shows potential for sarcoma treatment.

Conclusions:

• Metabolic enzyme alterations, particularly IDH mutations and SDH deficiency, represent a significant source of new therapeutic targets for sarcomas.
• Exploiting these specific metabolic vulnerabilities holds promise for advancing sarcoma treatment strategies.